Treatment of brain metastases (MTSC) by Whole Brain Radiotherapy (WBRT) and temozolomide (TMZ) concomitant - TEM09

AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE0 个研究点目标入组 120 人开始时间: 2009年10月1日最近更新: 2014年3月17日

适应症

试验速览

暂无简介。

•-Informed consent-written and signed; -Age ≥ 18 years; -Consideration histological / cytological known from the primary tumor; -At least one lesion measurable by repetitive cerebral CT and / or MRI with mdc, not candidates for surgery or radiosurgery; -No-encephalic radiotherapy made previously; -Cancer-therapy earlier interrupted by at least 2 weeks or depending on the adopted scheme of chemotherapy, where q 21, q 14, or q 7, respectively performed by three, two, or 1 week.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•-Severe comorbidity; -Women in pregnancy or lactation; -Pz, with single metastases, candidates for surgery or SRT; -Stroke-past cerebral vascular known; -MTS-cerebral bleeding; -MTS-brain from an unknown primary tumor; -Symptomatic cerebral atrophy present before treatment; -Treatment-encephalic radiotherapy performed previously, including SRT; -Treatment-chemotherapy in progress; antiblastic with chemotherapy drugs or with a molecular target, or ormonoterapia in progress.

发起方

AZIENDA OSPEDALIERA OSPEDALE S. SALVATORE